Navigation Links
Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
Date:4/11/2008

TUSTIN, Calif., April 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that the following preclinical abstracts will be the subject of oral and poster presentations at the 2008 Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego:

-- "Targeting mutant p53 protein and tumor vasculature: An effective

combination therapy for advanced breast tumors" (Abstract #2341, New

Targets 1: Mechanisms Session) - Poster session scheduled for Monday,

April 14, 2008 from 8:00 am to 12:00 pm.

-- "An immunocytokine that binds to phosphatidylserine generates an

effective cell-based tumor vaccine in mice" (Abstract #2841, Tumor

Vaccines Session) - Poster session scheduled for Monday, April 14,

2008 from 1:00 pm to 5:00 pm.

-- "Combination of a monoclonal anti-phosphatidylserine antibody with

docetaxel strongly inhibits the growth and metastasis of

hormone-refractory prostate cancers in mice" (Abstract #2551, New

Approaches to Biological Therapy Session) - Oral presentation

scheduled for Monday, April 14, 2008 at 2:10 pm.

-- "Antibody targeting of phosphatidylserine produces a cytokine

microenvironment that enhances innate anti-tumor immune responses"

(Abstract #4079, Immunoconjugates, Peptides, and Protein Therapeutics

Session) - Poster session scheduled for Tuesday, April 15, 2008 from

8:00 am to 12:00 pm.

Abstracts and information abou
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
2. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
3. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
8. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
9. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Marktech Optoelectronics has introduced the MTE280xxx series, its ... 280 nm wavelength range. This series joins Marktech’s current ... to 405nm. These new devices are suitable for applications ... Mark Campito, Marktech’s CEO states that “what makes this ... that we offer it in one of the largest ...
(Date:9/23/2014)... Dr. Williams says, “Find The Black Box ... a three phase process that can lead to the ... would go far beyond anything previously imagined. First everyone ... healthcare.” , “Every effort to improve the quality of ... progress throughout that system because all of the experts ...
(Date:9/23/2014)... September 23, 2014 Healthcare ... globe will convene at the Society for ... be held October 26-28 in Houston, Texas ... and practice in individualized integrative cancer care. ... nurses, psychologists, nutritionists, naturopaths, acupuncturists, and other ...
(Date:9/23/2014)... Plymouth, MN (PRWEB) September 23, 2014 ... named NimbeLink, a developer of cellular modems ... a finalist in the Startup category for the ... will be held at the Minneapolis Convention Center ... Minnesota companies and individuals who have shown superior ...
Breaking Biology Technology:Marktech Introduces its New Line of Deep UV Emitters 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3NimbeLink Named Finalist for 15th Annual Tekne Awards 2NimbeLink Named Finalist for 15th Annual Tekne Awards 3
... KONG, China , July 19 /PRNewswire/ - Aegera Therapeutics ... of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, ... (primary liver cancer). , , ... This study, entitled "A Phase 1-2, Open-Label Study of The ...
... announces that a new market research report is available in its catalogue: , ... Cells Market And Applications. 2009-2015 , , , ... , , REPORT ... The ,Stem Cells Market and Applications: (2009-2015), reviews the latest Stem Cells ...
... PARK, N.C. , July 16 Talecris Biotherapeutics Holdings Corp. (Nasdaq: ... on July 29, 2010 . Due to the pending merger with Grifols, S.A., ... , , , ... Dedication. Innovation. , , , ...
Cached Biology Technology:Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma 2Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma 3Reportlinker Adds Stem Cells Market And Applications. 2009-2015 2Reportlinker Adds Stem Cells Market And Applications. 2009-2015 3Reportlinker Adds Stem Cells Market And Applications. 2009-2015 4Reportlinker Adds Stem Cells Market And Applications. 2009-2015 5Reportlinker Adds Stem Cells Market And Applications. 2009-2015 6Reportlinker Adds Stem Cells Market And Applications. 2009-2015 7Reportlinker Adds Stem Cells Market And Applications. 2009-2015 8Reportlinker Adds Stem Cells Market And Applications. 2009-2015 9Reportlinker Adds Stem Cells Market And Applications. 2009-2015 10Reportlinker Adds Stem Cells Market And Applications. 2009-2015 11Reportlinker Adds Stem Cells Market And Applications. 2009-2015 12Reportlinker Adds Stem Cells Market And Applications. 2009-2015 13Reportlinker Adds Stem Cells Market And Applications. 2009-2015 14Reportlinker Adds Stem Cells Market And Applications. 2009-2015 15Reportlinker Adds Stem Cells Market And Applications. 2009-2015 16Reportlinker Adds Stem Cells Market And Applications. 2009-2015 17Reportlinker Adds Stem Cells Market And Applications. 2009-2015 18Reportlinker Adds Stem Cells Market And Applications. 2009-2015 19Reportlinker Adds Stem Cells Market And Applications. 2009-2015 20Reportlinker Adds Stem Cells Market And Applications. 2009-2015 21Reportlinker Adds Stem Cells Market And Applications. 2009-2015 22Reportlinker Adds Stem Cells Market And Applications. 2009-2015 23Reportlinker Adds Stem Cells Market And Applications. 2009-2015 24Reportlinker Adds Stem Cells Market And Applications. 2009-2015 25Reportlinker Adds Stem Cells Market And Applications. 2009-2015 26Reportlinker Adds Stem Cells Market And Applications. 2009-2015 27Reportlinker Adds Stem Cells Market And Applications. 2009-2015 28Reportlinker Adds Stem Cells Market And Applications. 2009-2015 29Reportlinker Adds Stem Cells Market And Applications. 2009-2015 30Reportlinker Adds Stem Cells Market And Applications. 2009-2015 31Reportlinker Adds Stem Cells Market And Applications. 2009-2015 32Reportlinker Adds Stem Cells Market And Applications. 2009-2015 33
(Date:9/21/2014)... are significantly less likely to report taking iron supplements ... children who are developing normally, a study by researchers ... Low iron intake was associated with a five-fold greater ... was 35 or older at the time of the ... such as obesity hypertension or diabetes. , The research ...
(Date:9/21/2014)... was previously thought, newborn immune T cells may have ... according to a new study led by King,s College ... that of adults, babies may still be able to ... in the journal Nature Medicine . , Our ... of immune cells, including neutrophils which play an important ...
(Date:9/19/2014)... biology professor will study the unique bioelectric signaling system ... benefit people,s health. The OU researcher is working ... to produce the signals used to map the world ... a rate of 500-600 discharges a second throughout their ... fish are extreme, but necessary for survival. , "There ...
Breaking Biology News(10 mins):Mothers of children with autism less likely to have taken iron supplements 2Immune system of newborn babies is stronger than previously thought 2
... 2009, the National Science Foundation (NSF) will host its ... This year,s forum focuses on ecological connectivity and ... In an ecological context, connectivity is defined as the ... and animals among interconnected locations. In this symposium, ...
... Seawater is a complex, dynamic mixture of ... scientists best efforts, presents difficulties in measuring its ... water itself, the calculations scientists employ to measure ... over the years as research techniques and instrumentation ...
... revolutionary new technology developed at The University of Nottingham ... far. Using a scientific technique known as Hydropyrolysis ... able to date chemical fossils discovered in sedimentary rocks ... fossil steroids, remnants of a type of sponge known ...
Cached Biology News:National Science Foundation forum to address ecological connectivity and climate in a changing world 2New equation of state of seawater 2New equation of state of seawater 3Engineering technology pinpoints earliest signs of animal life 2
... Camera hood with 5.6" TFT color screen, without ... system use digital camera with 8.0 mega pixel ... requirements and small budget. View image from large ... specific feature. It is suitable to capture image ...
... The binding specificity and signaling of the ... to be modified by alternative splicing--which has ... SpliceArrays you can perform a classical expression ... the different alternatively spliced forms of the ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... Apoptosis is an evolutionarily conserved form ... cellular process. The central component of ... enzymes called caspases. These enzymes participate ... triggered in response to pro-apoptotic signals and ...
Biology Products: